Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Healthtrust
Cantor Fitzgerald
AstraZeneca
Merck
McKinsey
Citi
Federal Trade Commission
Argus Health
Deloitte

Generated: January 21, 2018

DrugPatentWatch Database Preview

FORTAZ Drug Profile

« Back to Dashboard

Which patents cover Fortaz, and what generic alternatives are available?

Fortaz is a drug marketed by Teligent and is included in two NDAs.

The generic ingredient in FORTAZ is ceftazidime sodium. There are seventeen drug master file entries for this compound. Additional details are available on the ceftazidime sodium profile page.

US Patents and Regulatory Information for FORTAZ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teligent FORTAZ ceftazidime INJECTABLE;INJECTION 050578-002 Jul 19, 1985 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teligent FORTAZ IN PLASTIC CONTAINER ceftazidime sodium INJECTABLE;INJECTION 050634-003 Apr 28, 1989 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teligent FORTAZ ceftazidime INJECTABLE;INJECTION 050578-001 Jul 19, 1985 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teligent FORTAZ ceftazidime INJECTABLE;INJECTION 050578-003 Jul 19, 1985 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teligent FORTAZ ceftazidime INJECTABLE;INJECTION 050578-004 Jul 19, 1985 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teligent FORTAZ IN PLASTIC CONTAINER ceftazidime sodium INJECTABLE;INJECTION 050634-002 Apr 28, 1989 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teligent FORTAZ IN PLASTIC CONTAINER ceftazidime sodium INJECTABLE;INJECTION 050634-001 Apr 28, 1989 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice
AstraZeneca
Daiichi Sankyo
Covington
Julphar
McKesson
Baxter
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot